Cardiology Update

AUGUST 4, 2024

Despite proven benefits in reducing morbidity and mortality, many heart failure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF).

Heart Failure 119

Heart Failure ACE Inhibitor COVID-19 Quality of Life 119

All About Cardiovascular System and Disorders

APRIL 30, 2024

Hypertrophic cardiomyopathy is a genetic disorder with a guarded prognosis which occurs in about 1:500 individuals. The most common symptom of hypertrophic cardiomyopathy is dyspnoea which occurs in 90% of cases and is due to elevated left ventricular diastolic pressures as a consequence of the diastolic dysfunction.

Cardiomyopathy 40

Cardiomyopathy Bicuspid/Mitral Document Arrhythmia 40

All About Cardiovascular System and Disorders

MAY 14, 2024

Mavacamten is now approved for treatment of symptomatic hypertrophic obstructive cardiomyopathy and endorsed by mult-society guidelines. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy was published in 2023, with 28 patients on aficamten 13 on placebo. J Am Coll Cardiol. 2023 Jan 3;81(1):34-45.

Cardiomyopathy 40

Cardiomyopathy Biomarkers Heart Failure General Cardiology 40

All About Cardiovascular System and Disorders

APRIL 14, 2024

A triphasic left ventricular filling pattern with an additional mid diastolic wave, called T wave by some authors and L wave by others, can occur in situations of left ventricular diastolic dysfunction, especially in hypertrophic cardiomyopathy. One situation is decompensated advanced systolic heart failure with large left ventricle.

Bicuspid/Mitral 52

Bicuspid/Mitral Pulmonary Atrial Fibrillation Ultrasound 52

Cardiology Update

MARCH 17, 2024

Childhood-onset cardiomyopathies represent a rare and poorly understood subset of cardiac disorders. In a recent study published in the European Heart Journal, investigators delved into the demographics and prognosis of pediatric cardiomyopathy patients within the inaugural European Cardiomyopathy Registry. Eur Heart J.

Cardiomyopathy 119

Cardiomyopathy Pediatrics Article Heart Failure 119

All About Cardiovascular System and Disorders

FEBRUARY 25, 2024

When non-compaction is associated with left ventricular dysfunction it is called left ventricular non-compaction cardiomyopathy. Some of them may develop heart failure, arrhythmias, thromboembolic events and even sudden cardiac death rarely. Familial occurrence in up to 30% of first degree relatives have been noted [1].

Sudden Cardiac Death 52

Sudden Cardiac Death Heart Failure Cardiomyopathy Arrhythmia 52

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). Patients receiving semaglutide showed a greater change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary scores at 52 weeks than placebo.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52